芦可替尼治疗初治或糖皮质激素难治性儿童慢性移植物抗宿主病(REACH5):单臂、多中心、2期研究中分析
这项单臂2期研究在14个国家21家医院纳入45例2岁至<18岁、初治或糖皮质激素难治性中重度慢性GVHD患儿,口服芦可替尼联合糖皮质激素。第7周期第1天总缓解率为40.0%(18/45;90%CI 27.7-53.3),初治组7/17(41%)、激素难治组11/28(39%)。常见≥3级治疗相关不良事件为中性粒细胞减少8/45(18%)和血小板减少6/45(13%)。
要点
- 第7周期第1天总缓解率40.0%(18/45;90%CI 27.7-53.3)。
- 初治组缓解7/17(41%),糖皮质激素难治组缓解11/28(39%)。
- ≥3级治疗相关不良事件最常见为中性粒细胞减少8/45(18%)和血小板减少6/45(13%)。
核心结论
- 中分析显示芦可替尼在2岁至<18岁初治或糖皮质激素难治性慢性GVHD患儿中具有活性且耐受性良好,支持其在该人群中使用。
- 芦可替尼在该儿科人群中的安全性特征与成人一致。
- 最终分析将进一步提供芦可替尼在儿童慢性GVHD中长期获益的信息。
研究设计与样本
- 单臂、多中心、2期研究,在亚洲、欧洲和加拿大的14个国家21家医院或诊所招募患者。
- 纳入年龄28天至<18岁、接受过异基因HSCT、按2014年美国国立卫生研究院共识标准诊断的初治或糖皮质激素难治性中重度慢性GVHD患者。
- 芦可替尼按开始治疗时年龄给药:12岁至<18岁组10 mg每日两次,6岁至<12岁组5 mg每日两次,2岁至<6岁组4 mg/m2每日两次。
- 治疗以28天为周期给药约36个月,同时按机构指南给予支持治疗;主要活性终点为第7周期第1天总缓解率。
- 全分析集包括所有接受至少一剂芦可替尼的患者;本报告为预设的中分析,计划在所有患者完成1年治疗或停止治疗后进行,此处报告的主要终点评价结果视为最终结果。
主要发现
- 2020年5月20日至2021年9月17日筛查48例,45例入组并接受至少一剂研究药物;中位年龄11.0岁(IQR 7.2-14.3),女性16例(36%)、男性29例(64%)。
- 45例中White 21例(47%)、Black或African American 1例(2%)、Asian 23例(51%);初治17例(38%)、糖皮质激素难治28例(62%)。
- 截至数据截止日2022年10月19日,中位芦可替尼暴露55.1周(IQR 13.1-75.3),第7周期第1天总缓解率为40.0%(18/45;90%CI 27.7-53.3)。
- 初治组缓解7/17(41%),糖皮质激素难治组缓解11/28(39%)。
- 最常见的≥3级治疗相关不良事件为中性粒细胞减少8/45(18%)和血小板减少6/45(13%);7例(16%)发生≥3级严重治疗相关不良事件,最常见为低钠血症2/45(4%)。
关键数值与推荐
- 第7周期第1天总缓解率40.0%(18/45;90%CI 27.7-53.3)。
- 初治组第7周期第1天缓解7/17(41%),糖皮质激素难治组缓解11/28(39%)。
- ≥3级治疗相关不良事件:中性粒细胞减少8/45(18%),血小板减少6/45(13%)。
- ≥3级严重治疗相关不良事件7/45(16%),最常见低钠血症2/45(4%)。
- 治疗期间死亡3/45(7%),均认为与研究药物无关。
临床怎么用
- 作者认为,在最终分析前,本研究提示芦可替尼在2岁至<18岁初治或糖皮质激素难治性慢性GVHD患者中具有活性且耐受性良好,从而支持其在该患者人群中使用。
- 原文未据此给出其他推荐。
局限性
- 原文结论称待最终分析,本研究提示芦可替尼的活性与耐受性,最终分析将进一步提供长期获益信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Chronic graft-versus-host disease (GVHD) is a debilitating, and sometimes life threatening, complication of allogeneic haematopoietic stem-cell transplantation (HSCT). We aimed to investigate the activity, pharmacokinetics, and safety of ruxolitinib added to corticosteroids in paediatric patients (ie, <18 years) with moderate-to-severe chronic GVHD. METHODS: In this single-arm, phase 2 study, patients were recruited at 21 hospitals or clinics across 14 countries in Asia, Europe, and Canada. Eligible patients were aged 28 days to younger than 18 years, had undergone allogenic HSCT, and had been diagnosed with treatment-naive or corticosteroid-refractory moderate-to-severe chronic GVHD, per 2014 National Institutes of Health consensus criteria. Patients received oral ruxolitinib dosing on the basis of their age at the start of treatment: those aged 12 years to younger than 18 years received 10 mg twice daily (age ≥12 to <18 years group), those aged 6 years to younger than 12 years (age ≥6 to <12 years group) received 5 mg twice daily, and those aged 2 years to younger than 6 years received 4 mg/m2 twice daily (age ≥2 to <6 years group). Treatment was to be administered in 28-day cycles for approximately 36 months, alongside supportive treatment per institutional guidelines. The primary activity endpoint was overall response rate at cycle 7 day 1. Activity and safety analyses are reported in the full analysis set, which included all patients who received at least one dose of ruxolitinib. Here we report the prespecified interim analysis, scheduled to occur after all patients had completed 1 year of treatment or discontinued treatment, and the results for the primary endpoint evaluation reported here is to be considered final. This study is registered with ClinicalTrials.gov, NCT03774082, enrolment is complete, and the study is ongoing. FINDINGS: Between May 20, 2020, and Sept 17, 2021, 48 patients were screened, of whom 45 were enrolled and received at least one dose of study drug (median age was 11·0 years [IQR 7·2-14·3], 16 [36%] were female, 29 [64%] were male, 21 [47%] were White, one [2%] was Black or African American, 23 [51%] were Asian, 17 [38%] were treatment-naive, 28 [62%] were corticosteroid-refractory). As of data cutoff (Oct 19, 2022), after a median ruxolitinib exposure of 55·1 weeks (IQR 13·1-75·3), the overall response rate at cycle 7 day 1 was 40·0% (18 of 45; 90% CI 27·7-53·3), with responses seen in seven (41%) of 17 treatment-naive patients and 11 (39%) of 28 corticosteroid-refractory patients. The most common treatment-related adverse events of grade 3 or worse were neutropenia (eight [18%] of 45) and thrombocytopenia (six [13%]). Seven (16%) patients had grade 3 or worse serious treatment-related adverse events; the most common was hyponatraemia (two [4%] of 45). Three (7%) patients died while on-treatment (within 30 days of treatment discontinuation), one due to Aspergillus infection, one due to septic shock, and one due to acute respiratory distress syndrome; none were considered to be related to study drug. INTERPRETATION: Pending final analysis, this study suggests that ruxolitinib is active and well tolerated in both treatment-naive and corticosteroid-refractory patients aged 2 years to younger than 18 years with chronic GVHD, thereby supporting its use in this patient population. The safety profile of ruxolitinib in this patient population is consistent with that of adults. Final analysis of this study will provide further information on the long-term benefits of ruxolitinib in children with chronic GVHD. FUNDING: Novartis.
引用
- Locatelli F, Antmen B, Kang HJ, et al. Ruxolitinib in treatment-naive or corticosteroid-refractory paediatric patients with chronic graft-versus-host disease (REACH5): interim analysis of a single-arm, multicentre, phase 2 study. Lancet Haematol. 2024. PMID: 39002551. doi:10.1016/S2352-3026(24)00174-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。